Treats molluscum contagiosum. NDA 212905, held by Verrica Pharms. Cantharidin.
As of Nov 13, 2026, NDA 212905 (Ycanth), held by Verrica Pharms, was first approved by FDA on Jul 21, 2023, with 0 approved supplements and 3 published complete response letters.
YCANTH is indicated for the topical treatment of molluscum contagiosum in adult and pediatric patients 2 years of age and older.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 21, 2023 | Original applicationNew formulation or manufacturer · Standard review | Approved |
| Letter | Product | Now |
|---|---|---|
| May 23, 2022 | CantharidinFacility Inspections | Approved |
| Sep 16, 2021 | CantharidinFacility Inspections | Approved |
| Jul 13, 2020 | CantharidinProduct Quality, Facilities, Process | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Ycanth0.7% · solution;topical | Cantharidin | RxReference drug |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
